Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men
PERTH
1 other identifier
observational
50
1 country
1
Brief Summary
The purpose of this study is to examine the postprandial (anytime after a meal) effect of different dietary fats on endothelial function in HIV-infected and HIV-uninfected men.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2008
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2008
CompletedFirst Submitted
Initial submission to the registry
February 17, 2009
CompletedFirst Posted
Study publicly available on registry
February 18, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2010
CompletedOctober 12, 2017
October 1, 2017
2 years
February 17, 2009
October 11, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To measure flow-mediated dilation before and after eating the two study meals.
Study visit 1 and 2
Secondary Outcomes (1)
To compare the effect of different dietary fats on endothelial function.
Study visit 1 and 2
Study Arms (2)
1
High omega-3
2
High saturated fat
Interventions
Eligibility Criteria
HIV-infected white males who have identified themselves with concerns about diet or cardiovascular disease.
You may qualify if:
- HIV-positive white male aged \>18 years
- Under one of the following treatment categories:
- Treatment naive or have never taken any HIV medications
- Taking Kaletra
- Taking Sustiva
- Taking Atripla
You may not qualify if:
- Smoker
- Pre-existing diagnosis or treatment for the following:
- Lipid disorder
- Cardiovascular disease
- High blood pressure
- Diabetes
- Acute opportunistic infection or malignancy within last 3 months or current therapy for either
- Active IV drug use
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tufts Universitylead
Study Sites (1)
Tufts University
Boston, Massachusetts, 02111, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alexandra Mangili, MD, MPH
Tufts University School of Medicine
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 17, 2009
First Posted
February 18, 2009
Study Start
January 1, 2008
Primary Completion
January 1, 2010
Study Completion
January 1, 2010
Last Updated
October 12, 2017
Record last verified: 2017-10